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Figure 1. Frequency of Unexpected 99mTc-DPD Myocardial Uptake
Prevalence of myocardial tracer uptake according to age (A) and age and sex
(B) among the 12,400 patients who underwent 99mTc-3,3-diphosphono-1,2-
propanodicarboxylic acid (99mTc-DPD) scintigraphy.
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531visualized, thus avoiding inadvertent extension of the LA length
measurement into the pulmonary veindan error that results in
smaller LA volumes. In addition, there has been a lack of con-
sistency in methods used to calculate LAVi. Prior studies have
reported LA volumes using biplane area-length, biplane Simpson’s,
and prolate ellipsoid methods (1,2,4).
LAVi is considered a marker of diastolic dysfunction (1), with a
current cutoff value of 34 ml/m2 used to indicate elevated left
ventricular ﬁlling pressures in the setting of an E/E0 between 9 and
14. In our study, however, 30% of healthy subjects had a LAVi
$34 ml/m2 in the presence of normal echocardiographic indexes of
left ventricular ﬁlling pressures.
This study is a retrospective analysis, and measurements were not
performed blinded to the clinical data and thus are subject to se-
lection and information bias.
In conclusion, reassessment of LAVi in a contemporary healthy
cohort suggests higher normative reference ranges than previously
published. Establishing normative values for LA volumes are
important for clinical decision making, given the signiﬁcant asso-
ciation that has been reported between increased LA volume and
prognosis in a wide range of CV diseases.
Katrijn Jansen, MD, Navin Mani, BS, Praveen Mehrotra, MD,
Timothy C. Tan, MBBS, PhD, Xin Zeng, MD, PhD,
Danya Dinwoodey, MD, Michael H. Picard, MD, Judy Hung, MD*
*Blake 256, Massachusetts General Hospital, 55 Fruit Street, Boston,
Massachusetts 02114. E-mail: jhung@partners.org
http://dx.doi.org/10.1016/j.jcmg.2013.09.024
R E F E R E N C E S
1. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial
volume as a morphophysiologic expression of left ventricular diastolic
dysfunction and relation to cardiovascular risk burden. Am J Cardiol
2002;90:1284–9.
2. Pritchett AM, Jacobsen SJ, Mahoney DW, Rodeheffer RJ,
Bailey KR, Redﬁeld MM. Left atrial volume as an index of left
atrial size: a population-based study. J Am Coll Cardiol 2003;41:
1036–43.
3. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber
quantiﬁcation. Eur J Echocardiogr 2006;7:79–108.
4. Thomas L, Levett K, Boyd A, Leung DY, Schiller NB, Ross DL.
Compensatory changes in atrial volumes with normal aging: is atrial
enlargement inevitable? J Am Coll Cardiol 2002;40:1630–5.
Identiﬁcation of TTR-Related
Subclinical Amyloidosis
With 99mTc-DPD Scintigraphy
We have previously documented that 99mTc-3,3-diphosphono-1,2-
propanodicarboxylic acid (99mTc-DPD) has a high afﬁnity for
transthyretin (TTR)-inﬁltrated myocardium, allowing a differential
diagnosis with light-chain cardiac amyloidosis (1) and other non-
amyloidotic cardiomyopathies with a hypertrophic phenotype (2).
Notably, 99mTc-DPD allows an early diagnosis of TTR-related
cardiac amyloidosis, even before the appearance of overt echocar-
diographic or electrocardiographic abnormalities (3). However, the
potential role of this technique in the pre-clinical populationscreening has not been explored yet. We therefore evaluated prev-
alence and implications of incidental myocardial uptake among
patients undergoing 99mTc-DPD scintigraphy for oncologic/rheu-
matologic reasons.
We retrospectively analyzed all 99mTc-DPD scintigraphies per-
formed at our institution between 2008 and May 2013. Scintigraphy
protocol and image analysis have been previously described (1).
During the study period, 12,521 patients underwent scintigraphy,
including 121 with suspected cardiac amyloidosis: these patients were
excluded. The study population therefore consisted of 12,400 pa-
tients with oncologic (95%) or rheumatologic (5%) indications to
scintigraphy (37% men; mean age 74 years; range 65 to 82 years).
Myocardial tracer uptake was present in 45 subjects (0.36%; 62%
men; median age 81 years; range 77 to 84 years), and an associated
localized area of bone metastatic activity was present in a single case.
Speciﬁcally, myocardial uptake was strong in 40 cases (89%) and
moderate in 5 (11%). The prevalence of incidental uptake increased
progressively with age (Fig. 1).
Thirty-two of 45 patients showing myocardial uptake were
contacted and offered a comprehensive cardiological evaluation
including ECG, echocardiography, and endomyocardial biopsy in
selected cases. Fourteen patients agreed to be evaluated (11 men;
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532median age 82 years; range 70 to 88 years). Four patients were
symptomatic for dyspnea (New York Heart Association functional
class II); 1 had a pacemaker; 2 were receiving antihypertensive
therapy; carpal tunnel syndrome had been previously diagnosed in 3.
None had overt neurologic symptoms. ECG was abnormal in all
cases: atrial ﬁbrillation in 3 cases, left anterior hemiblock in 2,
isolated ST-T abnormalities in 4, abnormal Q waves in 3, and low
QRS voltage in 2. Increased left ventricular (LV) wall thickness was
detected in all patients (mean LV wall thickness, 14 mm; inter-
quartile range: 13 to 15 mm), and LV ejection fraction was 58%
(interquartile range: 54% to 67%). Other echocardiographic ab-
normalities included mild pericardial effusion (n ¼ 6), A-V valve
thickening (n ¼ 5), and myocardial granular sparkling (n ¼ 8). LV
“hypertrophy” was completely unexplained in 10 patients and was
out of proportion in 4 (moderate systemic hypertension with non-
dilated LV and ascending aorta). Genetic analysis was performed in
6 cases and documented an Ile68Leu TTR mutation in a single
patient. Endomyocardial biopsy was performed in the remaining 5
patients and detected TTR-related amyloidosis in all, leading to a
ﬁnal diagnosis of wild-type TTR amyloidotic cardiomyopathy (se-
nile systemic amyloidosis [SSA]).
In this large cohort of subjects undergoing 99mTc-DPD scintig-
raphy for different reasons, 45 (0.36%) showed unexpected
myocardial tracer uptake. We cannot exclude a slight underestima-
tion of the real prevalence because of the retrospective nature of the
study. The subsequent cardiological evaluation revealed an unex-
plained increase of LV wall thickness in all the analyzed cases, and
endomyocardial biopsy conﬁrmed the diagnosis of TTR-
related amyloidosis in all the patients who underwent the proce-
dure. The impact of our study, albeit small, mainly relies on the
possibility of an early (pre-clinical) identiﬁcation of patients affected
by TTR-related amyloidotic cardiomyopathy, mainly the form
related to the deposition of wild-type TTR, a condition that is
believed to be highly underdiagnosed. There are currently no reliable
studies regarding the prevalence of SSA. If we consider all our pa-
tients with myocardial 99mTc-DPD uptake to be affected by TTR-
related cardiomyopathy (mainly SSA), the prevalence of the disease
would reach 1.4% among men in the ninth decade. It is noteworthy
that although SSA is known to mainly affect elderly men, a relevant
number of women showed asymptomatic myocardial tracer uptake.
Finally, our data require conﬁrmation through prospective studies,
but, if conﬁrmed, they would suggest the possibility of using 99mTc-
DPD scintigraphy as a screening tool in populations at risk. With the
advent of new drugs aimed at halting TTR deposition that are
currently under clinical evaluation (4), an early diagnosis of the dis-
ease is highly encouraged and should be pursued.
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Diagnostic Problem of
LV Hypertrabeculation/
Noncompaction?
With interest we read the article by Stacey et al. (1) about systolic
and diastolic criteria for left ventricular hypertrabeculation/non-
compaction (LVHT). Uniform diagnostic criteria for LVHT are a
still unsolved problem in echocardiography as well as other imaging
modalities like cardiac magnetic resonance (CMR). Whether the
results of their investigations will lead to more clariﬁcation is
questionable due to the following reasons: 1) No pathoanatomic
gold standard is provided; thus, neither sensitivity nor speciﬁcity of
the proposed criteria can be assessed. 2) It remains uncertain in how
many patients LVHT was diagnosed by echocardiography. There is
a need to calculate the percentage of LVHT patients in whom
LVHT was diagnosed on echocardiography and CMR, on CMR
but not on echocardiography and on echocardiography but not on
CMR. 3) The duration and quality of follow-up remain uncertain.
Were follow-up data obtained for each of the included patients? 4)
Differentiation between LVHT on the one hand and papillary
muscles, false tendons, and aberrant bands on the other is a difﬁcult
issue because these structures are seen frequently, and there is
considerable anatomic variability (2,3). To our knowledge, the
proposed “papillary muscle classiﬁcation system” is not based on any
pathoanatomic classiﬁcation. Furthermore, it seems rather difﬁcult
to differentiate between papillary muscles and trabeculations when
only short-axis views are considered. Only by using longitudinal
views will it be possible to visualize the communication of the
papillary muscles with the mitral valve leaﬂets via the chordae ten-
dineae. Not to differentiate between LVHT and papillary muscles is
not acceptable because LVHT diagnostic criteria deﬁnitions clearly
exclude papillary muscles from the evaluation. 5) There is no need to
distinguish between “myopathic LVHT” and “normal variants”
because they are morphologically the same and have a similar
complication rate and outcome. Normal variants may have sub-
clinical myopathy or may have chromosomal abnormalities, which
manifest only in the heart. This is why we recommend referring all
LVHT patients to a myologist to also detect neurological abnor-
malities which are clinically inapparent for the cardiologist. As an
initial step, the authors should provide information about how many
of their patients had an elevated creatine kinase level and in how
many patients was LVHT familial. Familial LVHT may suggest
hereditary disease, including neuromuscular disorders.
Additionally, we have the following questions regarding the pre-
sented data. 1) It was previously reported that echocardiographically
